These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 17914581)

  • 1. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
    Skírnisdóttir I; Lindborg K; Sorbe B
    Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy.
    Skírnisdóttir I; Sorbe B
    Int J Gynecol Cancer; 2007; 17(6):1231-7. PubMed ID: 17425681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.
    Takei Y; Suzuki M; Ohwada M; Saga Y; Kohno T; Machida S; Sato I
    Oncol Rep; 2003; 10(4):951-5. PubMed ID: 12792751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
    Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy.
    Sato S; Shimada M; Ohta T; Kojimahara T; Tokunaga H; Takano T; Yamaguchi S; Tanabe H; Nishio S; Kigawa J
    Int J Gynecol Cancer; 2016 Mar; 26(3):561-7. PubMed ID: 26825829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
    Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
    Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
    Lydiksen L; Jensen-Fangel S; Blaakaer J
    Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
    Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
    Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past?
    Skirnisdottir I; Nordqvist S; Sorbe B
    Oncol Rep; 2005 Aug; 14(2):521-9. PubMed ID: 16012740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
    Bamias A; Karadimou A; Soupos N; Sotiropoulou M; Zagouri F; Haidopoulos D; Thomakos N; Rodolakis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2011 Oct; 123(1):37-42. PubMed ID: 21764430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic factors for survival of ovarian epithelial cancers: apropos of 287 cases].
    Brun JL; Bouzigon E; Saurel J; Chêne G; Briex M; Brun G; Hocke C
    Gynecol Obstet Fertil; 2000 Mar; 28(3):223-31. PubMed ID: 10786403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
    García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
    Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
    Takada T; Iwase H; Iitsuka C; Nomura H; Sakamoto K; Omatsu K; Takeshima N; Takizawa K
    Int J Gynecol Cancer; 2012 May; 22(4):573-8. PubMed ID: 22398705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
    Ueno Y; Enomoto T; Otsuki Y; Sugita N; Nakashima R; Yoshino K; Kuragaki C; Ueda Y; Aki T; Ikegami H; Yamazaki M; Ito K; Nagamatsu M; Nishizaki T; Asada M; Kameda T; Wakimoto A; Mizutani T; Yamada T; Murata Y
    Cancer Lett; 2006 Sep; 241(2):289-300. PubMed ID: 16459017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.
    Desai NB; Kiess AP; Kollmeier MA; Abu-Rustum NR; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Dec; 131(3):604-8. PubMed ID: 24055615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.